GSK vs. PODD: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at GSK and PODD, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
GSK trades as an American Depositary Receipt (ADR), offering U.S. investors a convenient way to access its foreign-listed shares. In contrast, PODD is a standard domestic listing.
| Symbol | GSK | PODD |
|---|---|---|
| Company Name | GSK plc | Insulet Corporation |
| Country | United Kingdom | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Pharmaceuticals | Health Care Equipment & Supplies |
| Market Capitalization | 89.72 billion USD | 21.76 billion USD |
| Exchange | NYSE | NasdaqGS |
| Listing Date | March 28, 1980 | May 15, 2007 |
| Security Type | ADR | Common Stock |
Historical Performance
This chart compares the performance of GSK and PODD by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | GSK | PODD |
|---|---|---|
| 5-Day Price Return | 10.83% | -0.48% |
| 13-Week Price Return | 18.15% | 2.68% |
| 26-Week Price Return | 10.65% | 17.71% |
| 52-Week Price Return | 12.85% | 32.88% |
| Month-to-Date Return | 4.60% | 0.12% |
| Year-to-Date Return | 22.32% | 18.40% |
| 10-Day Avg. Volume | 6.93M | 0.68M |
| 3-Month Avg. Volume | 5.82M | 0.70M |
| 3-Month Volatility | 26.97% | 30.36% |
| Beta | 0.99 | 1.39 |
Profitability
Return on Equity (TTM)
GSK
24.18%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.85%
- Q1
- 5.40%
- Min
- -10.91%
In the upper quartile for the Pharmaceuticals industry, GSK’s Return on Equity of 24.18% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
PODD
18.43%
Health Care Equipment & Supplies Industry
- Max
- 29.93%
- Q3
- 16.99%
- Median
- 9.28%
- Q1
- 5.10%
- Min
- -12.52%
In the upper quartile for the Health Care Equipment & Supplies industry, PODD’s Return on Equity of 18.43% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
Net Profit Margin (TTM)
GSK
10.82%
Pharmaceuticals Industry
- Max
- 40.67%
- Q3
- 19.07%
- Median
- 12.31%
- Q1
- 4.50%
- Min
- -9.91%
GSK’s Net Profit Margin of 10.82% is aligned with the median group of its peers in the Pharmaceuticals industry. This indicates its ability to convert revenue into profit is typical for the sector.
PODD
10.01%
Health Care Equipment & Supplies Industry
- Max
- 24.41%
- Q3
- 13.71%
- Median
- 10.08%
- Q1
- 5.96%
- Min
- -5.58%
PODD’s Net Profit Margin of 10.01% is aligned with the median group of its peers in the Health Care Equipment & Supplies industry. This indicates its ability to convert revenue into profit is typical for the sector.
Operating Profit Margin (TTM)
GSK
16.22%
Pharmaceuticals Industry
- Max
- 45.78%
- Q3
- 23.14%
- Median
- 16.68%
- Q1
- 7.98%
- Min
- -7.13%
GSK’s Operating Profit Margin of 16.22% is around the midpoint for the Pharmaceuticals industry, indicating that its efficiency in managing core business operations is typical for the sector.
PODD
12.01%
Health Care Equipment & Supplies Industry
- Max
- 31.09%
- Q3
- 18.11%
- Median
- 15.07%
- Q1
- 8.48%
- Min
- -0.28%
PODD’s Operating Profit Margin of 12.01% is around the midpoint for the Health Care Equipment & Supplies industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | GSK | PODD |
|---|---|---|
| Return on Equity (TTM) | 24.18% | 18.43% |
| Return on Assets (TTM) | 5.77% | 7.21% |
| Net Profit Margin (TTM) | 10.82% | 10.01% |
| Operating Profit Margin (TTM) | 16.22% | 12.01% |
| Gross Profit Margin (TTM) | 71.77% | 70.74% |
Financial Strength
Current Ratio (MRQ)
GSK
0.87
Pharmaceuticals Industry
- Max
- 4.65
- Q3
- 2.64
- Median
- 1.85
- Q1
- 1.26
- Min
- 0.78
GSK’s Current Ratio of 0.87 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
PODD
2.26
Health Care Equipment & Supplies Industry
- Max
- 5.19
- Q3
- 3.00
- Median
- 2.13
- Q1
- 1.44
- Min
- 0.86
PODD’s Current Ratio of 2.26 aligns with the median group of the Health Care Equipment & Supplies industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
GSK
1.17
Pharmaceuticals Industry
- Max
- 1.75
- Q3
- 0.82
- Median
- 0.35
- Q1
- 0.13
- Min
- 0.00
GSK’s leverage is in the upper quartile of the Pharmaceuticals industry, with a Debt-to-Equity Ratio of 1.17. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
PODD
0.96
Health Care Equipment & Supplies Industry
- Max
- 1.61
- Q3
- 0.76
- Median
- 0.45
- Q1
- 0.14
- Min
- 0.00
PODD’s leverage is in the upper quartile of the Health Care Equipment & Supplies industry, with a Debt-to-Equity Ratio of 0.96. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
Interest Coverage Ratio (TTM)
GSK
2.37
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 43.60
- Median
- 9.83
- Q1
- 2.37
- Min
- -42.71
GSK’s Interest Coverage Ratio of 2.37 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.
PODD
33.28
Health Care Equipment & Supplies Industry
- Max
- 56.35
- Q3
- 25.56
- Median
- 9.60
- Q1
- 3.78
- Min
- -26.49
PODD’s Interest Coverage Ratio of 33.28 is in the upper quartile for the Health Care Equipment & Supplies industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
Financial Strength at a Glance
| Symbol | GSK | PODD |
|---|---|---|
| Current Ratio (MRQ) | 0.87 | 2.26 |
| Quick Ratio (MRQ) | 0.57 | 1.55 |
| Debt-to-Equity Ratio (MRQ) | 1.17 | 0.96 |
| Interest Coverage Ratio (TTM) | 2.37 | 33.28 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
GSK
3.76%
Pharmaceuticals Industry
- Max
- 7.14%
- Q3
- 3.45%
- Median
- 2.17%
- Q1
- 0.33%
- Min
- 0.00%
With a Dividend Yield of 3.76%, GSK offers a more attractive income stream than most of its peers in the Pharmaceuticals industry, signaling a strong commitment to shareholder returns.
PODD
0.00%
Health Care Equipment & Supplies Industry
- Max
- 4.15%
- Q3
- 1.76%
- Median
- 0.79%
- Q1
- 0.00%
- Min
- 0.00%
PODD currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
GSK
54.01%
Pharmaceuticals Industry
- Max
- 199.58%
- Q3
- 97.17%
- Median
- 53.47%
- Q1
- 22.97%
- Min
- 0.00%
GSK’s Dividend Payout Ratio of 54.01% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
PODD
0.00%
Health Care Equipment & Supplies Industry
- Max
- 160.00%
- Q3
- 66.60%
- Median
- 27.49%
- Q1
- 0.00%
- Min
- 0.00%
PODD has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | GSK | PODD |
|---|---|---|
| Dividend Yield (TTM) | 3.76% | 0.00% |
| Dividend Payout Ratio (TTM) | 54.01% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
GSK
19.36
Pharmaceuticals Industry
- Max
- 45.19
- Q3
- 27.91
- Median
- 20.59
- Q1
- 15.08
- Min
- 3.79
GSK’s P/E Ratio of 19.36 is within the middle range for the Pharmaceuticals industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
PODD
93.06
Health Care Equipment & Supplies Industry
- Max
- 67.29
- Q3
- 47.01
- Median
- 30.94
- Q1
- 23.91
- Min
- 10.79
At 93.06, PODD’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Health Care Equipment & Supplies industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.
Price-to-Sales Ratio (TTM)
GSK
2.10
Pharmaceuticals Industry
- Max
- 8.87
- Q3
- 4.56
- Median
- 2.14
- Q1
- 1.58
- Min
- 0.11
GSK’s P/S Ratio of 2.10 aligns with the market consensus for the Pharmaceuticals industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
PODD
9.31
Health Care Equipment & Supplies Industry
- Max
- 9.49
- Q3
- 5.41
- Median
- 2.86
- Q1
- 2.07
- Min
- 0.74
PODD’s P/S Ratio of 9.31 is in the upper echelon for the Health Care Equipment & Supplies industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
Price-to-Book Ratio (MRQ)
GSK
3.84
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.99
- Median
- 2.48
- Q1
- 1.53
- Min
- 0.59
GSK’s P/B Ratio of 3.84 is within the conventional range for the Pharmaceuticals industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
PODD
15.11
Health Care Equipment & Supplies Industry
- Max
- 10.85
- Q3
- 6.56
- Median
- 3.53
- Q1
- 2.36
- Min
- 0.71
At 15.11, PODD’s P/B Ratio is at an extreme premium to the Health Care Equipment & Supplies industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
Valuation at a Glance
| Symbol | GSK | PODD |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 19.36 | 93.06 |
| Price-to-Sales Ratio (TTM) | 2.10 | 9.31 |
| Price-to-Book Ratio (MRQ) | 3.84 | 15.11 |
| Price-to-Free Cash Flow Ratio (TTM) | 14.21 | 57.46 |